Difference between revisions of "Bleomycin (Blenoxane)"
Warner-admin (talk | contribs) m (Text replacement - "Category:DNA synthesis inhibitors" to "Category:Human DNA synthesis inhibitors") |
|||
Line 27: | Line 27: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
− | * 7/31/1973: Initial FDA | + | * 7/31/1973: Initial approval |
+ | *3/21/2003: (oldest label available at Drugs@FDA): has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: [[Head and neck cancer|squamous cell carcinoma of the head and neck]] (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx); [[penile cancer|penis]]; [[cervical cancer|cervix]]; [[Vulvar cancer|vulva]]; [[Hodgkin lymphoma|Hodgkin’s disease]]; [[:Category:Non-Hodgkin lymphomas|non-Hodgkin’s lymphoma]]; [[testicular cancer]] (including embryonal cell, choriocarcinoma, and teratocarcinoma). | ||
==Also known as== | ==Also known as== |
Revision as of 03:00, 30 November 2020
General information
Class/mechanism: Exact mechanism unknown, but suspected to inhibit DNA synthesis, with some evidence inhibition of RNA and protein synthesis. When administered intrapleurally for malignant pleural effusion, bleomycin acts as a sclerosing agent.[1][2]
Route: IV, IM, SC, intrapleural
Extravasation: irritant or neutral, depending on reference
- 1 unit of bleomycin = 1 mg of bleomycin
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Adenocarcinoma of unknown primary
- Cutaneous basal cell carcinoma
- Cutaneous squamous cell carcinoma
- Diffuse large B-cell lymphoma
- Follicular lymphoma
- HIV-associated lymphoma
- Hodgkin lymphoma
- Hodgkin lymphoma, nodular lymphocyte-predominant
- Kaposi sarcoma
- Osteosarcoma
- Penile cancer
- Post-transplant lymphoproliferative disorder
- Testicular cancer
Patient drug information
- Bleomycin (Blenoxane) patient drug information (Chemocare)[3]
- Bleomycin (Blenoxane) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 7/31/1973: Initial approval
- 3/21/2003: (oldest label available at Drugs@FDA): has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: squamous cell carcinoma of the head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx); penis; cervix; vulva; Hodgkin’s disease; non-Hodgkin’s lymphoma; testicular cancer (including embryonal cell, choriocarcinoma, and teratocarcinoma).
Also known as
- Brand names: Blenoxane, Bleo, Bleocin, Bleocip, Bleopar, Bleowel
References
- Drugs
- Intracavitary medications
- Intramuscular medications
- Intravenous medications
- Subcutaneous medications
- Irritant
- Neutral
- Human DNA synthesis inhibitors
- Adenocarcinoma of unknown primary medications
- Cutaneous basal cell carcinoma medications
- Diffuse large B-cell lymphoma medications
- HIV-associated lymphoma medications
- Hodgkin lymphoma medications
- Hodgkin lymphoma, nodular lymphocyte-predominant medications
- Osteosarcoma medications
- Penile cancer medications
- Post-transplant lymphoproliferative disorder medications
- Cutaneous squamous cell carcinoma medications
- Testicular cancer medications
- Kaposi sarcoma medications
- FDA approved in 1973
- WHO Essential Cancer Medicine